Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening
- PMID: 10744092
- DOI: 10.1016/S0140-6736(00)02038-9
Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening
Abstract
Background: Whether some benign ovarian cysts can develop into cancerous cysts is not known. If a large proportion of ovarian cancers arose in this way, it might be possible to remove the benign cysts in a screening programme before they became malignant. We used follow-up data from a cohort of 5479 self-referred women without symptoms, who participated in a ultrasonographic-screening trial for early ovarian cancer between June, 1981, and August, 1987. We assessed whether the removal of persistent ovarian cysts from these women was associated with a reduction in the expected number of deaths from ovarian cancer in the cohort as a whole.
Methods: The expected number of deaths from all causes, all cancers, and ovarian, breast, and colorectal cancers were calculated for the study cohort by the standard life-table method. The actual number of deaths and each cause were obtained and the proportional mortality ratio was calculated for each cause of death.
Findings: 5135 (95%) of the participants in the original trial were traced. During the screening, five of these women were found to have stage I epithelial ovarian cancer and 88 had benign epithelial ovarian tumours. The number of reported deaths from all causes (387 [50% of expected]), all cancers (221 [71%]), and ovarian cancer (22 [90%]) was lower than expected because of the "healthy-volunteer effect". Proportional mortality ratios were 100% (by definition) for all cancers, 141% for breast cancer, 128% for ovarian cancer (95% CI 87.7-187.6, p=0.19), 84% for colorectal cancer, and 48% for lung cancer.
Interpretation: The removal of persistent ovarian cysts was not associated with a decrease in the proportion of expected deaths from ovarian cancer relative to other cancers during follow-up. For population-based screening of healthy women without a family history of ovarian cancer, a screening test is required that is specific and sensitive to early malignant disease, and inexpensive.
Comment in
-
The ovary: cysts, screening, and tamoxifen.Lancet. 2000 Jun 10;355(9220):2078-9. doi: 10.1016/s0140-6736(05)73537-6. Lancet. 2000. PMID: 10885385 No abstract available.
Comment on
-
Influence of origin of ovarian cancer on efficacy of screening.Lancet. 2000 Mar 25;355(9209):1028-9. doi: 10.1016/s0140-6736(00)02026-2. Lancet. 2000. PMID: 10744081 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
